OPmobility Reports Q1 Revenue Dip Amid Automotive Industry Slowdown 
Chinese Robotics Stocks React as Humanoid Robot Marathon Sparks Competition Concerns 
OpenAI's $20 Billion Cerebras Deal Signals Massive AI Infrastructure Push 
Anthropic CEO Meets Trump Officials to Discuss Powerful New AI Model Mythos 
China Food Delivery Stocks Dip as Regulators Crack Down on “Ghost Deliveries” 
How Technology Is Reshaping Modern Business: From Operations to Customer Experience 
JAPEX Shares Drop as Middle East Tensions Drive LNG Costs and Production Risks 
Apple Stock Dips as Tim Cook Steps Down, John Ternus Named Next CEO 
Ethiopian Airlines Expands Fleet with New Boeing 787 Dreamliner Order to Boost Global Routes 
SK Hynix Launches 192GB SOCAMM2 Memory for Nvidia’s Next-Gen AI Chips 
Tesla Q1 Earnings Preview: Robotaxi Delays and SpaceX Merger Speculation Grow 
Indian Refiners Use Yuan via ICICI Bank to Pay for Iranian Oil Under U.S. Sanctions Waiver 
Apple Wins ITC Ruling, Keeping Blood-Oxygen Feature on Apple Watch 
Huawei Expands Vietnam Presence Through Strategic Partnership with SHB Bank 
SpaceX President Gwynne Shotwell Earns $85.8M as IPO Buzz Grows 
Want to cut your energy bills? Here’s how five experts are doing it 
Eli Lilly in Talks to Acquire Kelonia Therapeutics for Over $2 Billion 
WALTHAM, Mass., March 18, 2016 -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, announced today it has completed its previously announced private placement of 4.4 million shares of common stock at a price of $35.19 per share. This transaction resulted in total gross proceeds to the Company of approximately $155 million. TESARO intends to use the proceeds from the financing primarily to support the development of its product pipeline and for general corporate purposes.
Existing investors affiliated with InterWest Partners, Kleiner Perkins Caufield and Byers and New Enterprise Associates, in addition to new investors the Australian Government Future Fund and the funds managed by the Ally Bridge Group participated in the offering. The offering was led by Kleiner Perkins and NEA, each of which made an investment of approximately $50 million. There were no placement agents used for this financing.
This offer and sale of the shares have not been registered under the Securities Act of 1933, as amended, or applicable state securities laws. The shares were offered only to accredited investors.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction.
About TESARO
TESARO is an oncology-focused biopharmaceutical company devoted to providing transformative therapies to people bravely facing cancer. For more information, visit www.tesarobio.com.
TESARO Investor/Media Contact: Jennifer Davis Sr. Director, Corporate Development & Investor Relations +1.781.325.1116 or [email protected]
